7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N-methyl-9H-carbazol-2-amine | 1181375-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N-methyl-9H-carbazol-2-amine
• 英文别名: 7-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-N-methyl-9H-carbazol-2-amine
• CAS: 1181375-95-0
• 化学式: C₁₉H₂₃FN₂O₃
• 分子量: 346.402
• InChiKey: XWWZUJSAORWKRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-amine 在 sodium methylate 、 sodium tetrahydroborate 、 水 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以56%的产率得到7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N-methyl-9H-carbazol-2-amine
  参考文献：
  名称：

  [EN] NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION
  [FR] NOUVEAUX AGENTS D'IMAGERIE POUR LA DÉTECTION D'UNE DYSFONCTION NEUROLOGIQUE

  摘要：

  本文披露了一种在哺乳动物中诊断阿尔茨海默病或其易感性的化合物和方法，该方法包括向哺乳动物投与一种放射标记化合物的诊断有效量，所述化合物选自放射标记黄酮类、香豆素类、咔唑类、喹诺酮类、色酮类、咪唑类和三唑类衍生物组成的群体，使化合物分布到脑组织中，并对脑组织进行成像，其中与正常控制水平的结合相比，化合物对脑组织的结合增加表明哺乳动物患有或有发展阿尔茨海默病的风险

  公开号：

  WO2009102498A1

文献信息

• Imaging Agents for Detecting Neurological Dysfunction
  申请人：Szardenings Anna Katrin

  公开号：US20120302755A1

  公开（公告）日：2012-11-29

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

  本文公开了一种诊断哺乳动物阿尔茨海默病或其易感性的化合物和方法，其中该方法包括向哺乳动物施加诊断有效量的放射性标记化合物，所述化合物选自放射性标记的咔唑衍生物和其衍生物以及三唑衍生物组成的群体，允许该化合物分布到脑组织中，并成像脑组织，其中与正常控制结合水平相比，化合物对脑组织的结合增加表明哺乳动物正在患有或有发展阿尔茨海默病的风险。
• Imaging Agents Useful for Identifying AD Pathology
  申请人：Kolb Hartmuth C.

  公开号：US20100098634A1

  公开（公告）日：2010-04-22

  Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.

  本文提供的化合物和组合物包含如下所述的公式，其中该化合物是一种淀粉样蛋白结合化合物。本发明的淀粉样蛋白结合化合物可以以适量的方式用于体内成像淀粉样沉积物，以区分含有淀粉样沉积物的神经组织和正常神经组织。本发明的淀粉样探针可以用于检测和定量测量包括唐氏综合症、家族性阿尔茨海默病在内的疾病中的淀粉样沉积物。在另一实施例中，这些化合物可以用于治疗或预防神经退行性疾病。本文还提供了一种使化合物分布到脑组织中并成像脑组织的方法，其中与正常结合水平相比，化合物与脑组织的结合增加表明哺乳动物正在患有或有发展神经退行性疾病的风险。
• Novel Imaging Agents for Detecting Neurological Dysfunction
  申请人：Kolb Hartmuth C.

  公开号：US20110046378A1

  公开（公告）日：2011-02-24

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease

  本文披露了一种诊断哺乳动物阿尔茨海默病或其易感性的化合物和方法，该方法包括向哺乳动物施用诊断有效量的放射性标记化合物，所述化合物选自放射性标记的黄酮类、香豆素类、咔唑类、喹啉酮类、香豆素酮类、咪唑类和三唑类衍生物组，使化合物分布到脑组织中，并成像脑组织，其中与正常结合水平相比，化合物与脑组织的结合增加表明该哺乳动物正在患有或有发展阿尔茨海默病的风险。
• NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION
  申请人：Kolb Hartmuth C.

  公开号：US20110091382A1

  公开（公告）日：2011-04-21

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

  本文披露了一种在哺乳动物中诊断阿尔茨海默病或其易感性的化合物和方法，该方法包括向哺乳动物中投与一种放射性标记化合物的诊断有效量，所述化合物选自放射性标记的黄酮，香豆素，咔唑，喹啉酮，香豆酮，咪唑和三唑衍生物组中的一种，使该化合物分布到脑组织中，并成像脑组织，其中与正常控制水平的结合相比，化合物与脑组织的结合增加表明该哺乳动物正在患有或有发展阿尔茨海默病的风险。
• Imaging agents for detecting neurological dysfunction
  申请人：Siemens Medical Solutions USA, Inc.

  公开号：US08318132B2

  公开（公告）日：2012-11-27

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

  本文披露了一种诊断哺乳动物患有阿尔茨海默病或其易感性的化合物和方法，该方法包括向哺乳动物施用诊断有效量的放射性标记化合物，所述化合物选自放射性标记的黄酮类、香豆素类、咔唑类、喹啉酮类、香豆素类、咪唑类和三唑类衍生物，使化合物分布到脑组织中，并成像脑组织，其中与正常对照水平相比，化合物与脑组织的结合增加表明哺乳动物正在患有或有发展阿尔茨海默病的风险。